Back to News
Market Impact: 0.3
GENFIT To Advance Nangibotide Into Phase 2 Trial For Acute-On-Chronic Liver Failure
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
GENFIT plans to advance nangibotide into a Phase 2 proof-of-concept trial for Acute-on-Chronic Liver Failure, a rare and life-threatening liver condition. The clinical-development milestone is a modest positive catalyst for the company, though efficacy, safety and commercialization remain unproven.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
GNFT0.55
More News
- Nasdaq Nears Correction as Amazon, Alphabet, Intel Disappoint Wall Street
- Binance’s $6.3 Billion Cyber Heist Shows Crypto Vulnerabilities
- Big Oil Scores $56 Billion Windfall on Spiking Fuel Prices
- Chevron speeds ahead in Venezuela while Exxon urges caution with a ‘little pinch of salt’
- Backbone of a beast – charting Nvidia's rise to networking titan
- OpenAI raises just $11bn of $30bn target as AI investor appetite cools